Get the Daily Brief
Latest Biotech News
J&J’s Icotyde wins FDA nod — Oral IL‑23 pill cleared for plaque psoriasis
The FDA approved Icotyde (icotrokinra), an oral IL‑23 receptor antagonist developed by Johnson & Johnson with Protagonist Therapeutics, for moderate-to-severe plaque psoriasis in adults and...
UCSF dual‑vector and Azalea show in vivo CAR‑T advances — programmable editing inside patients
Researchers at UCSF reported a dual‑vector platform that programs CAR‑T cells in vivo through cell‑specific delivery and site‑specific DNA integration, demonstrating stable CAR expression and...
Basecamp launches Trillion Gene Atlas — partners with Anthropic, Ultima and PacBio
Basecamp Research unveiled the Trillion Gene Atlas, a public–private initiative with Anthropic, Ultima Genomics, PacBio and NVIDIA infrastructure to massively expand environmental sequencing...
Single‑molecule peptide sequencing and new proteomics methods expand protein readout capabilities
Two independent breakthroughs promise to extend high‑resolution protein analysis: a single‑molecule peptide sequencing method that converts peptides into amplifiable DNA barcodes and a separate...
Lipid nanoparticles repurpose immune metabolism — new LNP designs revive exhausted T cells and boost vaccines
Engineers at the University of Pennsylvania reported a lipid nanoparticle (LNP) platform that reinvigorates exhausted T cells in solid tumors by altering immune metabolism and delivering...
US research funding shifts: OMB lifts NIH spending hold; Congress reauthorizes SBIR/STTR
The White House approved NIH apportionments, ending a months‑long OMB hold and allowing the agency to resume grant awards, hiring and program rollouts for fiscal 2026. NIH Director Jayanta...
Cell‑therapy scale‑up: experts call for AI, automation and workforce training; Sartorius launches integrated Eveo platform
Industry analysts and academic specialists identify automation, AI‑driven process control, and trained biomanufacturing staff as the most effective levers to relieve CAR‑T production constraints....
Bicycle Therapeutics cuts workforce after regulatory setback — lead ADC deprioritized
Bicycle Therapeutics announced a workforce reduction of roughly 30%, shelving or deprioritizing several trials after regulatory feedback deemed its registrational study design inadequate to...
FDA issues third CRL to Aldeyra — reproxalap fails to show consistent efficacy
The FDA issued a third complete response letter to Aldeyra Therapeutics for reproxalap, the company’s dry‑eye candidate, citing inconsistent efficacy across trials and a lack of substantial...
Engineered E. coli sustain intratumoral nitric oxide — vascular normalization boosts checkpoint therapy in mice
Multiple teams reported engineered Escherichia coli Nissle 1917 strains that sustain intratumoral nitric oxide (NO) production through synthetic circuits, promoting vascular normalization, myeloid...
CAR‑T made inside the body: targeted dual‑vector integration reported
Researchers demonstrated site‑specific integration of large DNA payloads to program CAR‑T cells directly in vivo, bypassing ex vivo manufacturing. A UCSF team led by Justin Eyquem reported the...
J&J’s oral IL‑23 pill wins FDA clearance — first major challenger to injectables
Johnson & Johnson and partner Protagonist secured FDA approval for Icotyde (icotrokinra), a once‑daily oral IL‑23 receptor antagonist for moderate‑to‑severe plaque psoriasis in adults and...
Protein sequencing leap: single‑molecule peptide reads and scalable platforms
Two independent teams published complementary advances that push protein sequencing toward single‑molecule resolution. Stanford researchers disclosed a scalable method for high‑precision protein...
Trillion Gene Atlas launched: AI partners aim to expand evolutionary data 100‑fold
Basecamp Research announced the Trillion Gene Atlas, a coalition with Anthropic, Ultima Genomics and PacBio to generate enormous environmental and organismal sequence datasets and feed them to AI...
Engineered E. coli sustains intratumoral NO — tumors sensitized to PD‑L1 blockade
Two complementary Nature Biotechnology papers reported engineering Escherichia coli strains (EcN platform) to sustain intratumoral nitric oxide (NO) production, remodel tumor vasculature and...
Nanoparticles rethink immunotherapy and vaccines: LNPs revive exhausted T cells and reprogram DC metabolism
Engineers at the University of Pennsylvania reported a lipid nanoparticle (LNP) platform that reverses T‑cell exhaustion in solid tumors and drives durable tumor control in preclinical models,...
Thymus health emerges as predictor of immunotherapy and long‑term outcomes
Large multi‑cohort analyses and AI‑enabled CT studies linked adult thymic status to cancer immunotherapy outcomes and long‑term mortality risk. A Nature study and supporting real‑world analyses...
Congress reauthorizes SBIR/STTR — early‑stage biotech funding restored
After a months‑long lapse, Congress passed reauthorization of SBIR and STTR programs, restoring critical federal seed funding for small biotech companies. The bipartisan vote clears five years of...
Scaling cell therapies: integrated manufacturing platforms and automation to cut bottlenecks
Sartorius unveiled the Eveo Cell Therapy Platform, an integrated system combining raw materials, closed‑system production modules and QC assays aimed at reducing capacity constraints for...
T‑cell engager funding surge: Crossbow, Excalipoint close major rounds
Two financing rounds underscored investor appetite for next‑generation T‑cell engager modalities. Crossbow Therapeutics raised $77 million to advance CBX‑250, a TCR‑mimetic engager derived with MD...